FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Journal: Lung Cancer (Amsterdam, Netherlands)
Published:
Authors
Alexander Spira, Byoung Cho, Enriqueta Felip, Edward Garon, Koichi Goto, Melissa Johnson, Natasha Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Yang, Xiaoqian Lu, Yong Jiang, Jack Huang, Morgan Lam, Marcin Kowanetz, Shirley Wang, John Le, Jerry Hsu, Cai-cun Zhou
Relevant Conditions